|
Market Closed -
Nasdaq
01:30:00 31/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 35.37 USD | +0.34% |
|
+2.61% | -1.42% |
| 29/10 | Indivior Shares Rise After Q3 Adjusted EPS, Revenue Top Estimates | MT |
| 29/10 | (INDV) Indivior Expects 2026 Net Revenue Range $1.30B to $1.37B, vs. FactSet Est of $1.33B | MT |
Company Valuation: Indivior Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,423 | 2,969 | 2,085 | 1,553 | 4,480 | 4,175 | - | - |
| Change | - | 22.54% | -29.76% | -25.5% | 188.39% | -6.81% | - | - |
| Enterprise Value (EV) 1 | 1,563 | 2,435 | 2,008 | 1,567 | 4,604 | 4,162 | 3,605 | 2,984 |
| Change | - | 55.81% | -17.52% | -21.95% | 193.72% | -9.59% | -13.39% | -17.22% |
| P/E | 12.8x | -57.2x | 1,527x | -34.5x | 21.9x | 9.51x | 8.62x | 7.88x |
| PBR | - | 59.3x | - | -8.02x | -45.8x | - | - | - |
| PEG | - | 0x | -15x | 0x | -0x | 0x | 0.8x | 0.84x |
| Capitalization / Revenue | 3.06x | 3.29x | 1.91x | 1.31x | 3.62x | 3.13x | 2.98x | 2.8x |
| EV / Revenue | 1.98x | 2.7x | 1.84x | 1.32x | 3.72x | 3.13x | 2.58x | 2x |
| EV / EBITDA | 7.74x | 10.8x | 6.97x | 4.64x | 10.8x | 5.71x | 4.56x | 3.47x |
| EV / EBIT | 8.36x | 11.5x | 7.47x | 5.02x | 11.1x | 6.04x | 4.89x | 3.75x |
| EV / FCF | 4.61x | -10.7x | -4.86x | -196x | -49.5x | 8.18x | 6.63x | 4.83x |
| FCF Yield | 21.7% | -9.32% | -20.6% | -0.51% | -2.02% | 12.2% | 15.1% | 20.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.35 | -0.38 | 0.01 | -0.36 | 1.64 | 3.72 | 4.105 | 4.49 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 791 | 901 | 1,093 | 1,188 | 1,239 | 1,332 | 1,400 | 1,489 |
| EBITDA 1 | 202 | 225 | 288 | 338 | 428 | 728.4 | 790.8 | 859.6 |
| EBIT 1 | 187 | 212 | 269 | 312 | 415 | 688.8 | 737.7 | 795.7 |
| Net income 1 | 205 | -53 | 2 | -48 | 210 | 474.3 | 530 | 582.9 |
| Net Debt 1 | -860 | -534 | -77 | 14 | 124 | -12.5 | -570 | -1,191 |
| Reference price 2 | 17.25 | 21.75 | 15.27 | 12.43 | 35.88 | 35.37 | 35.37 | 35.37 |
| Nbr of stocks (in thousands) | 1,40,437 | 1,36,489 | 1,36,551 | 1,24,970 | 1,24,854 | 1,18,035 | - | - |
| Announcement Date | 16/02/22 | 16/02/23 | 22/02/24 | 20/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.51x | 3.13x | 5.71x | - | 417.49Cr | |
| 41.54x | 14.06x | 31.11x | 0.48% | 1,26300Cr | |
| 39.99x | 6.71x | 18.89x | 1.95% | 66TCr | |
| 38.61x | 8.62x | 17.83x | 2.33% | 52TCr | |
| 21.74x | 5.27x | 13.12x | 2.48% | 39TCr | |
| 109.15x | 6.06x | 25.73x | 2.28% | 37TCr | |
| 23.19x | 5.97x | 14.41x | 2.71% | 31TCr | |
| 24.47x | 4.9x | 13.63x | 1.77% | 29TCr | |
| 29.56x | 7.53x | 13.48x | 2.16% | 25TCr | |
| -49.1x | 7.47x | 29.35x | 1.93% | 21TCr | |
| Average | 28.87x | 6.97x | 18.33x | 2.01% | 42.66TCr | |
| Weighted average by Cap. | 37.26x | 8.84x | 21.95x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- INDV Stock
- Valuation Indivior Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
